Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:PROKNASDAQ:SKYENASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.49-8.1%$1.93$1.29▼$7.85$273.19M1.261.50 million shs1.05 million shsPROKProKidney$0.84-6.4%$0.79$0.46▼$3.05$245.37M1.36625,541 shs297,259 shsSKYESkye Bioscience$2.05-5.5%$2.11$1.14▼$11.10$63.50M1.69367,157 shs128,600 shsTNXPTonix Pharmaceuticals$31.98-7.4%$25.07$6.76▼$137.25$234.25M2.09922,491 shs680,544 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-8.12%-4.23%+41.48%-4.23%-58.77%PROKProKidney-6.44%-14.25%+8.71%-14.77%-71.96%SKYESkye Bioscience-6.55%-15.61%+5.87%-17.96%-79.61%TNXPTonix Pharmaceuticals-7.41%-21.33%+44.84%+113.20%-71.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.3828 of 5 stars3.52.00.00.03.50.80.6PROKProKidney2.5752 of 5 stars3.20.00.00.03.84.20.6SKYESkye Bioscience1.7893 of 5 stars3.52.00.00.03.50.00.0TNXPTonix Pharmaceuticals3.3336 of 5 stars3.52.00.00.03.13.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50402.01% UpsidePROKProKidney 2.33Hold$4.50436.80% UpsideSKYESkye Bioscience 3.00Buy$16.60709.76% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,729.27% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, TNXP, PROK, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.005/13/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $11.003/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/APROKProKidney$306K801.86N/AN/A($4.84) per share-0.17SKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ATNXPTonix Pharmaceuticals$10.04M23.33N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.18N/AN/AN/AN/A-38.99%-33.90%8/11/2025 (Estimated)PROKProKidney-$35.47M-$0.60N/AN/AN/AN/AN/A-10.24%8/8/2025 (Estimated)SKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/ATNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest SKYE, TNXP, PROK, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18PROKProKidneyN/A17.0817.09SKYESkye BioscienceN/A14.1914.19TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/APROKProKidney51.59%SKYESkye Bioscience21.09%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%PROKProKidney41.49%SKYESkye Bioscience4.50%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableSKYE, TNXP, PROK, and ANNX HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Makes New $66,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14 at 3:17 AM | marketbeat.comMillennium Management LLC Lowers Holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14 at 3:11 AM | marketbeat.comTonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim” Hunter, to Board of DirectorsJune 13 at 3:25 PM | manilatimes.netTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.8% - Time to Sell?June 13 at 1:55 PM | marketbeat.comTonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?June 13 at 7:51 AM | seekingalpha.comTonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of DirectorsJune 13 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 10.1% - Here's What HappenedJune 12 at 2:48 PM | marketbeat.comTonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not PessimisticJune 12 at 2:00 PM | msn.comTonix Pharmaceuticals stock falls after announcing $225 million share offeringsJune 12 at 11:39 AM | investing.comTonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares TumbleJune 12 at 11:17 AM | benzinga.comTonix Shares Fall After Entering Sales, Purchase AgreementsJune 12 at 8:59 AM | marketwatch.comTonix Pharmaceuticals files $500M mixed securities shelf, shares down 15%June 12 at 6:34 AM | seekingalpha.comTonix Pharma Signs Major Sales Agreements for FundingJune 11 at 5:58 PM | tipranks.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 1.9% Higher - What's Next?June 11 at 1:26 PM | marketbeat.comTonix Pharmaceuticals Announces Presentation at the 2025 BIO International ConventionJune 10, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.8% - Here's What HappenedJune 9, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street ZenJune 8, 2025 | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded to "Hold" at Wall Street ZenJune 7, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 6.4% - Time to Buy?June 6, 2025 | marketbeat.comTonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025June 5, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.8% - What's Next?June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, TNXP, PROK, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$2.49 -0.22 (-8.12%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.63 +0.14 (+5.66%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.ProKidney NASDAQ:PROK$0.84 -0.06 (-6.44%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.88 +0.04 (+4.50%) As of 06/13/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Skye Bioscience NASDAQ:SKYE$2.05 -0.12 (-5.53%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.10 +0.05 (+2.49%) As of 06/13/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Tonix Pharmaceuticals NASDAQ:TNXP$31.98 -2.56 (-7.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$32.02 +0.04 (+0.14%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
